(1→3)-Β-D-Glucan

Measures Beta D glucan levels in the serum to help detect fungal infections in the bloodstream, like Candida or Aspergillus. It is commonly used for diagnosing invasive fungal diseases.

Also known as(1?3) Beta D Glucan (bdg)Serum (1?3) Beta D Glucan (bdg)Serum

Available via

Home Collection, Lab Visit

Contains

2 parameters

Earliest reports in

Next Day

Test details

(1→3)-Β-D-Glucan Test in Bengaluru Overview

The (1→3)-β-D-Glucan Test, also known as the Beta-D-Glucan (BDG) test, is a blood test used primarily to detect invasive fungal infections. It's a non-culture-based diagnostic tool that helps in the early detection of systemic fungal diseases, especially in immunocompromised patients.

Purpose of the Test

This test is used to detect the presence of fungal cell wall components (β-D-glucan) in the blood. It’s helpful for diagnosing:

  • Invasive candidiasis (Candida species)
  • Aspergillosis (Aspergillus species)
  • Pneumocystis jirovecii pneumonia (PJP)
  • Fusarium, Trichosporon, and other rare fungi

Who Should Get This Test?

  • Immunocompromised patients:
    • Cancer patients on chemotherapy
    • Organ transplant recipients
    • People with HIV/AIDS
    • ICU patients with prolonged illness
  • Patients with suspected invasive fungal infections but negative cultures
  • When fungal infection is suspected in lungs, blood, or deep tissues

Who Should Get This Test?

  • Immunocompromised patients:
    • Cancer patients on chemotherapy
    • Organ transplant recipients
    • People with HIV/AIDS
    • ICU patients with prolonged illness
  • Patients with suspected invasive fungal infections but negative cultures
  • When fungal infection is suspected in lungs, blood, or deep tissues

What is Beta-D-Glucan?

  • (1→3)-β-D-glucan is a polysaccharide found in the cell walls of many fungi.
  • It is released into the bloodstream during an active fungal infection.
  • This test does not detect fungal DNA or the organism itself — it detects this fungal cell wall component.

Advantages of BDG Test

  • Early diagnosis — can detect infection before symptoms or imaging
  • Non-invasive
  • Helps guide antifungal therapy decisions
  • Useful for monitoring response to treatment

Clinical Use of BDG Test

Early Detection of Invasive Fungal Infections (IFIs)

  • Detects fungal infections before cultures or imaging are positive
  • Used in patients at high risk (immunocompromised, ICU, post-transplant, etc.)
  • Helps guide early antifungal therapy, which can be life-saving.
Preparations

No special preparations needed

Test included
(1→3)-Β-D-Glucan includes 2 parameters

  • (1-3)-beta-d-glucan
  • Result

Test code

5569

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
SerumYellow Vacutainer2 ML

Specimen stability information

Serum

Specimen rejection criteria

Test run frequency

Every Day TIME - 11:00

Turn around time

Next Day

Performing locations

Department

  • Eia - Infectious Section

CPT and Loinc codes

(1→3)-Β-D-Glucan

7500